Stefan A Koerber1,2,3, Maximilian T Utzinger4, Clemens Kratochwil4,5, Claudia Kesch6, Matthias F Haefner1,2,3, Sonja Katayama1,2,3, Walter Mier4, Andrei H Iagaru7, Klaus Herfarth1,2,3, Uwe Haberkorn4,5, Juergen Debus1,2,3, Frederik L Giesel8,5,9. 1. Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany. 2. Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany. 3. National Center of Radiation Oncology (NCRO), Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany. 4. Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany. 5. Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany. 6. Department of Urology, University Hospital Heidelberg, Heidelberg, Germany. 7. Division of Nuclear Medicine and Molecular Imaging, Stanford Health Care, Stanford, California; and. 8. Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany frederik@egiesel.com. 9. German Cancer Consortium (DKTK), Heidelberg, Germany.
Abstract
68Ga-prostate-specific membrane antigen (PSMA) PET/CT is a promising diagnostic tool for patients with prostate cancer. Our study evaluates SUVs in benign prostate tissue and malignant, intraprostatic tumor lesions and correlates results with several clinical parameters. Methods: One hundred four men with newly diagnosed prostate carcinoma and no previous therapy were included in this study. SUVmax was measured and correlated with biopsy findings and MRI. Afterward, data were compared with current prostate-specific antigen (PSA) values, Gleason score (GS), and d'Amico risk classification. Results: In this investigation a mean SUVmax of 1.88 ± 0.44 in healthy prostate tissue compared with 10.77 ± 8.45 in malignant prostate lesions (P < 0.001) was observed. Patients with higher PSA, higher GS, and higher d'Amico risk score had statistically significant higher PSMA uptake on PET/CT (P < 0.001 each). Conclusion: PSMA PET/CT is well suited for detecting the intraprostatic malignant lesion in patients with newly diagnosed prostate cancer. Our findings indicate a significant correlation of PSMA uptake with PSA, GS, and risk classification according to the d'Amico scale.
68Ga-prostate-specific membrane antigen (PSMA) PET/CT is a promising diagnostic tool for patients with prostate cancer. Our study evaluates SUVs in benign prostate tissue and malignant, intraprostatic tumor lesions and correlates results with several clinical parameters. Methods: One hundred four men with newly diagnosed prostate carcinoma and no previous therapy were included in this study. SUVmax was measured and correlated with biopsy findings and MRI. Afterward, data were compared with current prostate-specific antigen (PSA) values, Gleason score (GS), and d'Amico risk classification. Results: In this investigation a mean SUVmax of 1.88 ± 0.44 in healthy prostate tissue compared with 10.77 ± 8.45 in malignant prostate lesions (P < 0.001) was observed. Patients with higher PSA, higher GS, and higher d'Amico risk score had statistically significant higher PSMA uptake on PET/CT (P < 0.001 each). Conclusion:PSMA PET/CT is well suited for detecting the intraprostatic malignant lesion in patients with newly diagnosed prostate cancer. Our findings indicate a significant correlation of PSMA uptake with PSA, GS, and risk classification according to the d'Amico scale.
Authors: Chen Liu; Teli Liu; Zhongyi Zhang; Ning Zhang; Peng Du; Yong Yang; Yiqiang Liu; Wei Yu; Nan Li; Michael A Gorin; Steven P Rowe; Hua Zhu; Kun Yan; Zhi Yang Journal: J Nucl Med Date: 2020-02-07 Impact factor: 10.057
Authors: Martin T Freitag; Claudia Kesch; Jens Cardinale; Paul Flechsig; Ralf Floca; Matthias Eiber; David Bonekamp; Jan P Radtke; Clemens Kratochwil; Klaus Kopka; Markus Hohenfellner; Albrecht Stenzinger; Heinz-Peter Schlemmer; Uwe Haberkorn; Frederik Giesel Journal: Eur J Nucl Med Mol Imaging Date: 2017-10-16 Impact factor: 9.236
Authors: Xiaoxi Ling; Joseph D Latoche; Cindy J Choy; Brenda F Kurland; Charles M Laymon; Yijen Wu; Nathan Salamacha; Ding Shen; Jonathan J Geruntho; Lora H Rigatti; Hillarie P Windish; Beatrice Langton-Webster; Clifford E Berkman; Carolyn J Anderson Journal: Mol Imaging Biol Date: 2020-04 Impact factor: 3.488
Authors: Robert M Hicks; Jeffry P Simko; Antonio C Westphalen; Hao G Nguyen; Kirsten L Greene; Li Zhang; Peter R Carroll; Thomas A Hope Journal: Radiology Date: 2018-09-18 Impact factor: 11.105
Authors: Chen Liu; Teli Liu; Ning Zhang; Yiqiang Liu; Nan Li; Peng Du; Yong Yang; Ming Liu; Kan Gong; Xing Yang; Hua Zhu; Kun Yan; Zhi Yang Journal: Eur J Nucl Med Mol Imaging Date: 2018-05-02 Impact factor: 9.236
Authors: Stefan A Koerber; Leon Will; Clemens Kratochwil; Matthias F Haefner; Henrik Rathke; Christophe Kremer; Jonas Merkle; Klaus Herfarth; Klaus Kopka; Peter L Choyke; Tim Holland-Letz; Uwe Haberkorn; Juergen Debus; Frederik L Giesel Journal: J Nucl Med Date: 2018-07-05 Impact factor: 10.057